EAG Laboratories brings together the most respected names in contract research and testing services to strengthen our multi-disciplinary expertise. So whether your challenge is to accelerate research and development, solve manufacturing problems or ensure compliance with industry and governmental regulations, there’s always one answer. Ask EAG. We Know How.
Articles by
Today, about half of all therapeutic drug approvals by the US Food and Drug Administration (FDA) are for biological drugs. That number is expected to rise to 75 percent by 2025. When these biologics come off patent, the gates will open for a flood of biosimilar drugs (biopharmaceutical generics) that are designed to be much…
Currently, there are more than 75 antibody drug conjugates (ADCs) in various stages of pre-clinical and clinical development. The combination of a targeted antibody coupled with a cytotoxic small-molecule drug (via a flexible linker) makes for a lethal and specific oncologic drug product. However, an ADC is a heterogeneous cocktail of molecules with a range…